Volume 22, Issue 1 (September 1998)
Research in Medicine 1998, 22(1): 11-21 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Assadian H. The Combination Therapy with Bromocriptine and Cyproheptadine in Patients with Acromegaly. Research in Medicine 1998; 22 (1) :11-21
URL: http://pejouhesh.sbmu.ac.ir/article-1-2225-en.html
URL: http://pejouhesh.sbmu.ac.ir/article-1-2225-en.html
Endocrine Research Center, Ayatollah Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abstract: (3113 Views)
The therapeutic efficacy of the combination of cyproheptadine and bromocriptine was studied in 15 patients with active acromegaly showing incomplete GH suppression in response to bromocriptine therapy alone. The mean basal plasma GH was 31.3±5.5 µg/L, and it decreased to 19.0±3.9 µg/L during the single bromocriptine therapy (10-20 mg for 2 to 21 months). When cyproheptadine (12 to 16 mg for 8 to 52 month) was added to bromocriptine therapy, plasma GH decreased further (9.4±3.0 µg/L: vs pretreatment, P<0.001: vs bromocriptine treatment, P<0.005), and GH normalization was obtained in 8 patients. The plasma somatomedin-c levels in these 8 patients (0.3-1.8 U/ml) were within the normal range
during the combination therapy. Plasma GH responses to TRH or GHRH were markedly suppressed in 6 patients during the combination therapy compared to pretreatment or during bromocriptine treatment. In addition, a clear reduction in the tumor size was observed in 4 of 7 previously untreated patients during the combination therapy. In conclusion, cyproheptadine has therapeutic efficacy in acromegalic patients who showed incomplete GH suppression in response to treatment with bromocriptine alone.
Following the cyproheptadine and bromocriptine combination therapy tumor shrinkage was observed in some patients.
during the combination therapy. Plasma GH responses to TRH or GHRH were markedly suppressed in 6 patients during the combination therapy compared to pretreatment or during bromocriptine treatment. In addition, a clear reduction in the tumor size was observed in 4 of 7 previously untreated patients during the combination therapy. In conclusion, cyproheptadine has therapeutic efficacy in acromegalic patients who showed incomplete GH suppression in response to treatment with bromocriptine alone.
Following the cyproheptadine and bromocriptine combination therapy tumor shrinkage was observed in some patients.
Type of Study: Original |
Subject:
Interdisciplinary (Educational Management, Educational research, Statistics, Medical education
Received: 2020/02/18 | Accepted: 2020/02/18 | Published: 2020/02/18
Received: 2020/02/18 | Accepted: 2020/02/18 | Published: 2020/02/18
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This Journal is licensed under a Creative Commons Attribution 4.0 International License | Research in Medicine
Designed & Developed by : Yektaweb